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Case presentation
A 54-year-old white man was admitted to the New England Medical
Center (NEMC) for a percutaneous renal biopsy. Four years earlier
mild hypertension and 3+ proteinuria had been discovered during a
routine physical examination. At that time the serum creatinine was 1.2
mg/dI and the BUN was 15 mg/dl. Intravenous pyelography revealed
normally functioning kidneys; the right measured 12.5 cm and the left
13.5 cm. Treatment with hydrochlorothiazide and reserpine was begun.
Two and one-half years before admission, the serum creatinine was 1.8
mg/dl and the BUN was 24 mg/dl. One and one-half years before
admission, urinalysis revealed 4+ protein and 15 to 25 red blood cells
per high-power field; the serum creatinine was 2.1 mg/dl and the BUN
29 mg/dl. Three months prior to admission the serum creatinine was 2.6
mg/dl and the BUN 28 mg/dl; 24-hour urine protein excretion was 12 g.
Physical examination revealed a blood pressure of 200/100 mm Hg.
Funduscopic examination showed only arteriovenous nicking. The
lungs were clear to percussion and auscultation. Cardiac examination
revealed normal SI and S2 sounds without rubs, murmurs, or gallops.
There was 1 + pretibial edema. The remainder of the examination was
unrevealing.
Laboratory studies revealed the following pertinent data. Urinalysis
disclosed a specific gravity of 1.017, a pH of 6, 2+ protein, and 2+
blood. Microscopic examination of the sediment revealed 50 to 80 red
blood cells and I to 3 white blood cells per high-power field, hyaline
casts, and one pigmented cast. A urine culture was sterile. The serum
creatinine was 3.8 mg/dl and the BUN was 38 mg/dl. The 24-hour urine
protein excretion was 5.7g. Light microscopic study of the renal biopsy
material revealed benign nephrosclerosis and acute interstitial nephritis
with eosinophils predominating in the cell infiltrate. Immunofluores-
cence microscopy revealed 4+ mesangial deposits of IgA, trace to 2+
mesangial deposits of IgG, trace to 3+ mesangial deposits of C3, trace
to 1+ mesangial deposits of C4, and no 1gM; these findings were
thought to be diagnostic of IgA nephropathy. A short course of
prednisone, given to treat possible diuretic-induced allergic interstitial
nephritis, had no demonstrable effect, and the patient's renal function
continued to deteriorate. Sixteen months after the renal biopsy was
performed, the serum creatinine was 10.2 mg/dl and the BUN was ill
mg/dl. Hemodialysis was instituted and plans were made for renal
transplantation.
Discussion
DR. JosE L. RoDiclo (Jefe del Servicio de Nefrologia,
Ciudad Sanitaria de la Seguirdad Social J0 de Octubre, Madrid,
Spain): Before considering the manifestations of this interesting
condition and its features in the patient presented today, let us
first define IgA nephropathy and distinguish it from other renal
diseases.
Definition
Berger and Hinglais first characterized IgA nephropathy in
1968 [1], although Galle and Berger had described a similar
glomerular nephropathy with "intercapillary fibrinoid depos-
its" in 1962 [2], and Galle had observed these deposits on
electron microscopy in 1964 [3]. Idiopathic IgA nephropathy is
characterized pathologically by the presence of diffuse, granu-
lar mesangial IgA deposits and, by definition, by the absence of
any recognizable systemic disease. All the patients originally
described by Berger with IgA mesangial glomerulonephritis or
idiopathic IgA nephropathy had normal renal function, macro-
or microscopic hematuria, and proteinuria. Both the hematuria
and proteinuria were exacerbated by upper respiratory tract
infections [1, 4—6].
Because diffuse mesangial IgA deposits are observed in a
variety of disorders, the diagnosis of idiopathic IgA nephrop-
athy can be made only by exclusion. These associated disorders
include alcoholic cirrhosis [7—10] and certain systemic diseases
[11—17]. The systemic diseases in which mesangial deposits of
IgA are regularly observed include Henoch-Schönlein purpura
[11—13], systemic lupus erythematosus [14, 15], acute hepatitis
[16], and ankylosing spondylitis [17]. Finally, these deposits
occasionally have been found in patients with familial immun-
othrombocytopenia [18, 19], pulmonary hemosiderosis [20],
and scieritis [21].
There is a lack of uniformity in the literature in the definition
of IgA nephropathy. Some authors include every patient whose
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biopsy discloses IgA in the mesangium whether or not systemic
disease coexists [7—17]. Because the clinical presentation and
prognosis are related to the cause of this disorder, interpreta-
tion of studies grouping all patients with IgA mesangial deposits
together is difficult. Therefore, in this analysis I have reserved
the term idiopathic IgA nephropathy for only those patients in
whom systemic disease has been excluded.
Clinicalfeatures
Our experience is based on 140 cases of idiopathic IgA
nephropathy studied in the Jimenez Diaz Foundation and 10 de
Octubre Hospital in Madrid. The 140 cases represent 24% of all
the primary glomerulonephritis observed in both hospitals
during the last 6 years. The incidence of idiopathic IgA
nephropathy varies widely from one country to another; it is
only 2% to 8% in the United States, the United Kingdom, and
Canada [6, 14, 15, 22—251; 18% to 25% in France, Italy, and
Australia [1, 26—29]; and 21% to 34% in Japan [30, 31]. The
explanation for this apparent variability in incidence is uncer-
tain, but it might be related in part to differences in the
indications for renal biopsy at various locations. Berger, Yan-
eva, and Crosnier observed that IgA nephropathy was responsi-
ble for 10% of all cases of advanced renal insufficiency in
transplanted patients whose kidneys were studied histologically
[27].
The patient population is 65% to 89% male [1, 14, 24, 29, 32—
35], and the incidence peaks between ages 10 and 30 years [26,
36—381. The age and sex distribution at initial presentation of
IgA nephropathy in our series is listed in Table I. Reports of
familial occurrence among siblings [7, 39—411 and offspring [42,
43] suggest that this disease might have a hereditary origin.
Studies of histocompatibility antigens in idiopathic IgA
nephropathy are incomplete. In some studies, a greater fre-
quency of certain antigens was found in the patients compared
to controls, but other studies have failed to verify this associa-
tion. Similar confusion exists regarding the possible prognostic
implications of the histocompatibility antigens: recent studies
suggest, for example, that HLA-DR4 is associated with a poor
prognosis [43] and others with a good prognosis [44].
Recurrent macroscopic hematuria, usually associated with a
respiratory tract infection, is the most frequent clinical manifes-
tation [14, 22, 24, 45]. In some patients the disease presents as
an acute nephritic syndrome [29, 35], or acute renal failure, and
rarely as nephrotic syndrome [291. Occasionally the only mani-
festations are asymptomatic arterial hypertension, microhema-
tuna, or proteinuria alone or in combination. These abnormali-
ties are often identified during a routine medical evaluation [14,
221.
The clinical manifestations of idiopathic IgA nephropathy are
exemplified by our experience with 140 patients with the
disorder, of whom 76% presented with episodes of recurrent
macroscopic hematuria; 80% of the cases were associated with
upper respiratory tract infections, mainly acute pharyngotonsil-
litis. These figures conform closely to observations in other
series [14, 15, 22, 24, 29, 33, 35, 46]. Typically gross hematuria
appeared simultaneously or within the first 48 to 72 hours after
the infection began, persisted less than 3 days, and sometimes
was accompanied by lumbar pain [14]. Studies have demon-
strated a bacterial cause of the infection in only a small number
of cases [47], and investigators generally believe that most of
these infections are viral.
Table 1. Age and sex distribution in IgA nephropathy
Age
Male Female
Number of Number of
(years) patients % patients %
0—10 8 5.7 4 2.9
10—20 38 27.2 15 10.7
20—30 22 15.7 17 12.1
30—40 16 11.4 4 2.9
40—50 10 7.2 3 2.1
50—60 3 2.1 — —
Total 97 693 43 303
Episodes of hematuria have been associated with a variety of
other infections including lobar pneumonia, staphylococcal
osteomyelitis, staphylococcal sepsis, acute gastroenteritis, in-
fluenza, infectious mononucleosis, and brucellosis. Episodes
also have followed tonsillectomy, vaccination, tooth extraction,
violent physical exercise, and trauma [29, 48]. Between epi-
sodes of gross hematuria, many patients have persistent micro-
hematuria, proteinuria, or both. Proteinuria rarely reaches the
"nephrotic range." In our patients we commonly observed
intervals in which the urinary abnormalities completely disap-
peared. Microhematuria disappeared completely between at-
tacks in 30%, proteinuria resolved in 27%, and both remitted in
15%, for periods ranging from 4 months to 4 years [35]. Patients
with arterial hypertension never had spontaneous remissions.
In 15% of our patients, IgA nephropathy was first diagnosed
after asymptomatic microhematuria and proteinuria were found
on routine examination, and in 2.5% after detection of protein-
uria alone. The frequency of IgA nephropathy among patients
who first manifest asymptomatic hematuria and/or proteinuria
and normal renal function is unknown because many physicians
do not consider renal biopsy appropriate in such patients.
Further, renal biopsies frequently are not performed in patients
with hypertension and coexisting minor amounts of hematuria,
or proteinuria. We believe that some of these patients, usually
diagnosed as having "essential hypertension," actually suffer
from idiopathic IgA nephropathy, and the finding of elevated
IgA serum level in this group suggests that diagnosis. I will
discuss interpretation of the serum IgA level in more detail
later.
In 4% of our 140 patients and in 10% of patients in the series
of Clarkson et al [29], IgA nephropathy presented as an acute
nephritic syndrome similar to acute poststreptococcal glomeru-
lonephritis: features included gross hematuria, edema, hyper-
tension, proteinuria, and reduction of the glomerular filtration
rate. In our patients, all the clinical manifestations of nephritic
syndrome remitted spontaneously, but microhematuria persist-
ed. In 2.5% of our 140 patients, idiopathic IgA nephropathy had
a gradual onset, with symptoms attributable to chronic renal
insufficiency and coexistent hypertension, as described by
others [24, 25]. Indeed the patient presented today had a similar
presentation. During a routine examination, he was found to
have renal dysfunction. During the 4 years prior to the biopsy,
his renal insufficiency progressed. At the time of the biopsy the
serum creatinine level was 3.8 mg/dl. Instances of idiopathic
IgA nephropathy first appearing with malignant hypertension
and acute renal failure have been reported [7], but we have not
observed any such case. Moreover, we have observed no
Idiopathic IgA nephropathy 719
sions in both disorders. A high IgA serum level also has been
reported in alcoholic cirrhosis [57].
Mean values for salivary IgA also rise in patients with
idiopathic IgA nephropathy and correlate closely with serum
IgA levels [35, 57]. Reductions in serum C3 or C4 levels were
not detected in any of our patients or those of others [14, 29, 34,
47—49, 58, 59]. In the past, immune complexes in the serum of
patients with idiopathic IgA nephropathy were infrequently
detected [49, 60—65]. Recently, however, using more sensitive
techniques, researchers have identified IgA immune complexes
in as many as 40% to 60% of these patients [64, 65]. Serum
cryoglobulins were detected in 15% of our patients; however,
rheumatoid factor was found in only one of these individuals.
Neither serum C-reactive protein, hepatitis B antigen, antinu-
clear antibodies, nor anti-DNA antibodies were detected.
Pathologic features
patients in whom nephrotic syndrome was the initial
manifestation.
Although nephrotic syndrome is rare as a presenting manifes-
tation, it appears during the course of idiopathic IgA nephrop-
athy in 10% to 30% of patients [26, 29, 34, 35, 49, 50] and can
either persist or spontaneously remit. Arterial hypertension
also appears during the evolution of the disease, and although in
some series its incidence has been as low as 10% [1, 15, 22], in
others hypertension occurs in 32% to 62% [24, 26, 29]. In our
patients 29% developed hypertension and 20% had the nephrot-
ic syndrome. Both nephrotic syndrome and hypertension are
poor prognostic indicators.
Figure 1 represents the survival rates for 140 patients over 20
years. The upper line indicates that 95% of patients survived 5
years after the appearance of the initial symptoms, 87% lived 10
years, and 80% were alive 20 years later. The lower line depicts
the percentage of patients who survive with normal renal
function over time. Normal renal function (measured by creati-
nine clearance) was preserved in 73% for 5 years, 65% for 10
years, and 50% for 20 years. Thus chronic renal failure develops
frequently, but renal insufficiency usually progresses slowly
[26, 29, 35, 50, 51]. After 10 or 20 years the survival rate is 80%
or more [28, 52, 53]. In 8% of our patients, dialysis was started
after a followup period ranging from 2 to 15 years after the
disease appeared clinically. Five of these patients received a
renal transplant from a cadaver donor. Despite a relatively high
frequency of recurrence of this disease in transplanted kidneys
[54, 55], I believe that transplantation is not contraindicated
because of the slow progression of renal failure in this entity
[53].
Fifty percent of our patients with idiopathic IgA nephropathy
had high levels of serum IgA; this finding is consistent with the
results of others [14, 29, 33, 36, 38, 51, 56]. The high serum IgA
level is a diagnostic aid, but it is not pathognomonic of
idiopathic IgA nephropathy. We have observed high levels of
IgA in 12% of our patients with idiopathic membranoprolifera-
tive glomerulonephritis, 12% of patients with focal sclerosis,
33% of patients with lupus nephritis, and 54% of patients with
glomerulonephritis associated with Henoch-SchOnlein purpura.
In systemic lupus erythematosus and in Henoch-Schönlein
purpura with nephropathy, the rise in serum IgA coincides with
the clinical activity of the disease; serum IgA levels return to
normal during spontaneous or therapeutically induced remis-
Idiopathic IgA nephropathy is a form of proliferative glomer-
ular disease characterized by prominent mesangial deposition
of IgA. The first reported series emphasized the focal and
segmental character of the proliferative lesion observed on light
microscopy [1, 37]. Since then most authors have indicated that
the glomeruli usually are diffusely affected, showing different
grades of mesangial proliferation with or without segmental
proliferative changes (endothelial, mesangial and/or crescent
formation) [1, 66]. Moreover, many instances have been report-
ed in which immunofluorescent studies reveal IgA in the
glomeruli, yet the glomeruli show little or no change by light
microscopy. Neither necrotic capillary loops nor membranous
glomerulopathy is seen in idiopathic IgA nephropathy. The
widening of the mesangial areas is due to mesangial cell
proliferation and increased mesangial matrix (Fig. 2); this
matrix material is recognized as a moderately PAS-positive
material that stains bright red with Masson's trichrome. This
material corresponds to the electron-dense deposits observed
on electron microscopy and to the granular IgA deposits seen
by immunofluorescence. The diffuse mesangial proliferation is
not accompanied by endothelial proliferation or involvement of
the peripheral capillary walls. However, as many as 20% [67] of
patients have extracapillary proliferation with crescent forma-
tion that can be found in a large fraction of the glomeruli [68].
Fibrous crescents and mesangial sclerosis can produce glomer-
ular sclerosis. Nonspecific findings of vascular sclerosis, inter-
stitial fibrosis, and tubular atrophy frequently accompany ad-
vanced glomerular abnormalities.
I prefer to think about the glomerular morphology in idiopath-
ic IgA nephropathy as a spectrum of morphologic changes from
"normal" to marked mesangioproliferative glomerulonephritis.
In ascending order of severity, intermediate stages in this
spectrum consist of minimal glomerular changes, widening of
the mesangial area, segmental proliferation of mesangial cells,
and diffuse proliferation of mesangial cells. Crescent formation
usually is associated with the more severe lesions. Unfortunate-
ly the lack of uniform criteria for identifying these various
lesions has led to large differences in the fraction of patients
reported to have each variety (Table 2).
The immunofluorescence findings are the pathologic hall-
mark of this disease [1, 22, 33, 37, 68—71] and are summarized in
Table 3. Characteristically, IgA is deposited in a diffuse granu-
lar pattern in the mesangium (Fig. 3), and it also appears in the
peripheral capillary walls in 15% to 50% of the cases. Other
100
90
80
70
60
50
40
30
20
10
>
>
(I,
* —*
2 4 6 8 10 12 14 16 18 20
Time, years
Fig. 1. Actuarial survival curves over 20 years for 140 patients with
idiopathic IgA nephropathy. Circles denote renal actuarial survival;
stars denote survival with normal GFR.
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Fig. 2. Light photomicrograph showing moderate increase of mesangial matrix and slight proliferation of mesangial cells (HEx 250).
Table 2. Light microscopy glomerular patterns in idiopathic IgA
nephropathy
Diffuse
Focal mesangio-
Nor- Minimal segmental proliferative
mal changes changes changes
(%) (%) ('?7o) (?7c)
Druet et a! [261
(52 cases) 0 38.4 5.7 48
Levy et al [47]
(92 cases) 0 28.2 45.6 26.2
Morel-Maroger et al [33]
(98 cases) 2 0 86.6 11.4
Sakai et al [67]
(130 cases) 0 19.2 19.2 61.6
Gartner et al [321
(153 cases) 2 18 5 75
Southwest Pediatric
Nephrology Study
Group [66]
(62 cases) 25.8 0 33.8 50.4
Navas Palacios et al [701
(60 cases) 0 1.8 29.1 67.3
immunoglobulins usually accompany IgA including IgG, 1gM,
and IgE; C3 is almost always present, and CIq and C4 have been
found in many instances. Properdin has been demonstrated in
30% to 93% of the specimens examined. Fibrinogen is found in
the crescents and in the mesangial areas of 10% to 50% of the
specimens. Extraglomerular immunofluorescent deposits are
rarely found. Granular deposits sometimes appear in the base-
ment membrane of Bowman's capsule [22], tubular basement
membrane [26], and arterioles [15, 22]. Most of these extraglo-
merular deposits contain C3, although arteriolar IgA deposits
are rarely seen [15]. Extrarenal deposits of IgA also have been
reported in skin capillaries [72, 73] and in blood vessels of
skeletal muscle [74].
The ultrastructural manifestations of IgA nephropathy are
summarized in Table 4. Using electron microscopy, we found
mesangial deposits in all glomeruli we studied (Fig. 4). Never-
theless, there are several reported cases without such deposits
[66, 67, 71, 75]; the explanation for the absence is uncertain.
Subendothelial deposits are infrequent in the peripheral capil-
lary walls, and, when present, they are located close to the
mesangial stalks; however, true peripheral subendothelial de-
posits do occur [26, 66, 68, 70, 71, 76, 77]. Dense intramembran-
ous deposits also occur [66, 68, 70, 71, 75, 77] and scattered
subepithelial deposits have been reported [66, 70]. Dense
granular deposits also have been demonstrated in the basement
membrane of Bowman's capsule and in subendothelial regions
of extraglomerular arterioles [22, 701. Structural changes of the
lamina densa, such as thinning and splitting, are frequent [67,
70, 71, 75, 77].
F,.
I
I
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Table 3. Immunofluorescence findings in idiopathic IgA nephropathy
IgA
IgG
(%)
1gM
(%)
IgE
(%)
Fibr.
(%)
Prop.
(%)
C3
(%)
C4
(%)
Clq
(%)
Mesangi
(%)
at Parietal
(%)
Zollinger and Mihatsch [711
Druet et al [261
Southwest Pediatric Nephrology Study
Group [66)
McCoy et al 122]
Zimmerman and Burkholder [14]
Gartner et a! [32]
Navas Palacios et a! [701
100
100
100
100
100
100
100
50
17.3
23
NM
NM
24.2
10
83.3
69.2
77
60
82.2
45.8
45.4
66.6
16.6
22
60
66.6
31.3
9
NW
NM
NM
NM
NM
2.4
1.8
8.3
14.9
45
50
68.7
NM
10.8
NM
NM
29
87.5
83.3
NM
NM
100
80.6
77
85
100
95.3
43.5
NM
NM
24
0
20
NM
0
NM
NM
15
0
0
NM
1.8
a NM refers to data not mentioned.
Fig. 3. Light photomicrograph of a tissue section stained with anti-IgA labeled with isothiocyanate offluorescein. There are widespread mesangial
deposits of IgA, with occasional parietal staining (x250).
Several investigators have tried to identify morphologic pre-
dictors of the clinical course. Marked diffuse mesangial prolif-
eration, glomerular sclerosis, and interstitial fibrosis are associ-
ated with an unfavorable prognosis [50, 78]. Lee et al [68]
applied Meadows' [79] morphologic classification of Henoch-
Schönlein glomerulonephritis to idiopathic IgA nephropathy.
Grades IV and V (characterized by marked diffuse mesangial
proliferation and sclerosis with crescent formation) usually
were followed by progressive renal failure. There have been
several attempts at correlating ultrastructural findings with the
light microscopic changes. Hara et al divided patients with
histologic lesions into two types based on the presence or
absence of subendothelial deposits and found that patients with
deposits had a greater tendency to develop renal insufficiency
[80]. Sakai et al [67] and Shigematsu et al [77] have suggested
that alterations of the lamina densa might have prognostic
significance in that this structural change correlates with seg-
mental glomerular lesions and crescent formation.
As 1 mentioned earlier, deposition of IgA in the mesangium
occurs in disorders other than idiopathic IgA nephropathy. The
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Table 4. Ultrastructural findings in idiopathic IgA nephropathy
Deposits Lamina densa
SEpa(9)
1Mb
(%)
SEn
(9)
MESd
(%)
BMCBe(i) Arteriole(%) Thin(91') Split(91) Cases(%)
Druet et al [261
McCoy et al [22]
Zimmerman and Burkholder [14]
Alexander et al [15]
Clarkson et al [29]
Zollinger and Mihatsch [71]
Burkholder et at [75]
Sakai et al [671
Hara et al [80]
Navas Palacios et al [70]
Lee et a! [68]
Southwest Pediatric Nephrology Study
Group [66]
—
—
—
—
56
7.1
4.2
—
2.1
33
—
10
—
—
—
—
60
28.5
10
—
8.4
10
5
9
—
—
23
—
48
35.7
—
—
42
18.5
25
16
100
100
100
100
100
71.4
97.8
91.3
100
100
80
96.5
—
10
—
—
—
—
—
—
—
3.3
—
—
—
10
—
—
—
—
—
—
—
6.6
—
—
—
—
—
—
33
—
4.2
—
—
19.8
—
40
—
—
—
—
—
21.4
—
24.6
—
13.2
—
40
42
10
13
15
50
14
47
69
46
30
20
58
a SEp refers to subepithelial.
b IM refers to intramembranous.
SEn refers to subendothelial.
d MES refers to mesangial.
BMCB refers to basement membrane of Bowman's capsule.
nephritis of Henoch-Schönlein purpura can be pathologically
identical [64]. Light microscopy shows diffuse mesangial prolif-
eration, segmental lesions, or both. The frequency of certain
features does differ, however. In particular, epithelial cres-
cents, glomerular loop necrosis, and vasculitis appear more
frequently in Henoch-Schönlein purpura. Whereas immunoflu-
orescence studies demonstrate similar findings [81], mesangial
fibrinogen deposition occurs in a higher percentage of patients
with Henoch-Schönlein purpura. Glomerular involvement in
systemic lupus erythematosus has a pleomorphic character
[82]; mesangial IgA deposits similar to those in idiopathic IgA
nephropathy, necrosis, diffuse mesangial-endocapillary prolif-
eration, and membranous changes can be observed. Manigand
Ct al [83] and Callard et al [91 detected IgA mesangial deposits in
most patients with alcoholic cirrhosis. Variable amounts of IgA
in the glomeruli also are found in other primary glomerulone-
phntides [15, 501.
Diagnosis
As I have stressed, the clinical manifestations of idiopathic
IgA nephropathy are extremely varied, and the disorder thus
can resemble a large number of renal diseases and syndromes.
When one suspects idiopathic IgA nephropathy because of the
clinical manifestations in a given patient, the diagnosis can be
either confirmed or excluded by the associated clinical manifes-
tations, by measurements of IgA in the serum and, of course, by
renal biopsy. Clinical suspicion should be particularly high in
patients with recurrent gross hematuria that follows an upper
respiratory infection by a day or two, and in such cases the
diagnosis can be inferred from this history alone.
When the diagnosis is in doubt, measuring the level of IgA in
the serum can be useful because IgA levels are increased in 50%
to 70% of patients with idiopathic IgA nephropathy [29, 53, 56,
84], a substantially greater fraction than in other renal diseases
that mimic this disorder. A definitive diagnosis depends, of
course, on renal biopsy. When the biopsy demonstrates the
typical findings I have described, and the patient has no
manifestations of the other diseases that can produce this
histologic picture (such as Henoch-Schönlein purpura, lupus, or
liver disease), idiopathic IgA nephropathy can be diagnosed
with confidence.
Treatment
Considering the benign course followed by most patients with
this disease, treatment with steroids, immunosuppressive
drugs, or anticoagulants is not warranted. However phenytoin,
which reduces serum IgA levels [85—88], has been used in an
attempt to improve outcome in these individuals. In a con-
trolled trial, Clarkson et al observed no change in the clinical or
pathologic evolution of the disease in 23 patients treated with 5
to 6 mglkglday of phenytoin for 2 years [89]. Although levels of
IgA in the serum decreased in 74% of the patients treated, no
significant morphologic changes were observed in the biopsies
after treatment, and in all cases IgA deposits persisted in the
mesangium.
Egido and coworkers reported the results of a long-term
controlled trial with phenytoin [901. The treated group com-
prised 41 patients; the control, 32 patients. The number of
episodes of macroscopic hematuria per year decreased in both
groups, but was significantly lower at each time period in the
treated group than in the control one (treated group 1.92 + 0.7
episodes per first year and 0.39 + 0.20 episodes per year at the
third year; control group, 1.95 + 0.8 episodes per first year and
0.97 + 0.43 episodes per year at the third year). Unfortunately,
phenytoin did not influence either the pathologic lesions or the
progression of the disease. Because progression to renal failure
in these patients occurs over many years, however, more
observations of treated and untreated patients are needed
before we conclude that phenytoin is ineffective.
Fig. 4. Representative electron micrographs from patients with IgA nephropathy. A Large paramesangial deposits between the glomerular
basement membrane and mesangial cell. (EM x 9600) B Subendothelial deposit associated with thinning and splitting of the lamina densa. (EM x
12,800)
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Questions and answers
Da, JEROME P. KASSIRER: In patients with idiopathic IgA
nephropathy, what is known about the mechanism of the gross
hematuria that follows a respiratory tract infection by 24 to 48
hours? Is fever alone responsible? Is a previous lesion in the
kidney exacerbated by the infection? Is it mediated by immune
complexes?
DR. RoDiclo: This phenomenon is poorly understood.
Among pathogenetic mechanisms mentioned, I am not con-
vinced that the mechanism involves immune complexes be-
cause the time between the infection and gross hematuria seems
too short for such a reaction, There is some evidence, however,
that an antibody mechanism is operative. Perhaps we can ask
Dr. Egido, who has studied this question, to comment.
DR. JESUS EGID0 (Servicio NefrologIa, Fundación Ji,nenez
Diaz, Madrid): The appearance of macroscopic hematuria
following upper respiratory tract infections might a priori occur
by the acute deposition of immune complexes, immune com-
plex-like substances (such as polymeric IgA) or in-situ complex
formation at the mesangial level. As Dr. Rodicio pointed out,
the short interval between the infection and the hematuria argue
against a role for immune complexes. In a recent study we
examined the hypothesis that, after viral infection or other
stimuli, circulating lymphocytes from secretory tissues could
produce a large amount of polymeric IgA 9l]. In fact, polymer-
ic IgA increased in most patients after polyclonal stimulation of
peripheral mononuclear cells in vitro. Whether these large
polymers of IgA are able to reach the mesangium in vivo and
produce inflammation is not yet known.
DR. KASSHtER: In your view, are the kidneys of these patients
normal before the respiratory tract infection, or do these
patients have preexisting lesions?
DR. EGID0: In a disease with a long and indolent course such
as IgA nephropathy, it is not known when the pathologic
changes first appear. One can only hypothesize that chronic
deposition of IgA as immune complexes, in polymeric forms, or
both, might occur. It is possible that the mesangium can deal
with the deposited IgA initially, but that it later fails to clear the
material. The gross hematuria could be produced by an acute
deposition of a large amount of IgA or IgG in the forms
described above. It does seem clear that IgA remains in the
mesangium for long periods because repeated renal biopsies,
even in terminal chronic renal failure, always show IgA.
DR. VICTOR MILLET (Servicio Nefrologla, Ciudad San itaria,
10 de Octubre): If it is true that IgA is present in the kidneys
during asymptomatic intervals, then a renal biopsy should be
diagnostic in a patient suspected of IgA nephropathy during
intervals in which hematuria is not present.
DR. RoDiclo: Yes, and for this reason it is not necessary to
perform a biopsy only when the disease is in its symptomatic
phase.
DR. Luis HERNANDO (Jefe, Servicio NefrologIa, FundaciOn
Jimenez Diaz): I would like to comment on a peculiar form of
acute renal failure rarely observed in idiopathic IgA nephrop-
athy. In one of our patients with IgA nephropathy and acute
renal failure, dialysis was necessary for about one week, but the
patient's renal function recovered completely. The renal histol-
ogy did not differ in this patient from that observed in other
patients with IgA nephropathy.
DR. SANCHEZ SICILTA (Jefe, Servicio de NefrologIa, Ciudad
Sanitaria de la Paz, Madrid): We have seen a similar patient but
with two different episodes of acute renal failure. Dialysis was
needed each time but each time renal function returned to
normal. Gross hematuria accompanied the first episode but not
the second. Renal biopsy performed during the first admission
showed mesangial IgA deposits.
DR. R0DICI0: One of our patients with idiopathic IgA
nephropathy sustained a reduction in glomerular filtration rate
in association with gross hematuria following a respiratory tract
infection. He did not need dialysis, and renal function returned
to normal 2 weeks later. A similar episode occurred on another
occasion in the same patient.
DR. EGID0: I suspect that acute deposition of IgA in the
mesangium led to the reduction in GFR in these interesting but
rare patients.
DR. KASSIRER: There has been some confusion in the litera-
ture about the definition of IgA nephropathy. In some reports
all patients were included in whom IgA was found in the
mesangium, whether or not the patients had systemic disease or
alcoholic cirrhosis. You made a clear distinction today between
idiopathic IgA nephropathy and other nephropathies in which
IgA is found in the mesangium. Would you comment on the
value of this distinction?
DR. RoDIclo: Idiopathic IgA nephropathy is a well-defined
clinicopathologic entity. It is true that the histologic findings are
the same in Henoch-SchOnlein purpura and in some cases of
alcoholic cirrhosis and systemic lupus erythematosus. The
corollary is that one should always study a patient for a
systemic disease or liver disease if a renal biopsy discloses IgA
deposits.
DR. EGID0: In some cases it is very difficult to separate
idiopathic IgA nephropathy from other systemic diseases on
clinical grounds. We have seen some patients who had purpura
coincident with one episode of gross hematuria but who never
had purpura again, even though gross hematuria recurred. It
seems that some patients cannot strictly be assigned to a
category of idiopathic IgA nephropathy or to Henoch-Schönlein
purpura, and that they belong to what might be called the
spectrum of IgA nephropathy. Furthermore, since IgA is fre-
quently observed postmortem in the kidneys of patients with
alcoholic liver disease, one wonders whether patients with IgA
nephropathy and a history of chronic alcohol ingestion, with or
without clinical liver changes, must be considered as having
idiopathic IgA nephropathy. I believe that such patients must
be eliminated from series studying clinical, pathogenetic, or
therapeutic aspects of idiopathic IgA nephropathy if the study is
to examine a homogenous group of cases.
Commentary on the pathogenesis of IgA nephropathy
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center, and Assistant Professor of Medicine,
Tufts University School of Medicine): The events leading to IgA
production, glomerular IgA localization, and glomerulonephri-
tis in patients with idiopathic IgA nephropathy are not well
understood. Recent investigation has provided some insight
into the pathogenesis of this entity, however. Before reviewing
these studies, it is worth noting that idiopathic IgA nephropathy
might not be a single disease entity. As Dr. Rodicio has pointed
out, patients with IgA in their kidneys have been grouped
together even though their clinical manifestations and long-term
prognoses are variable. The specific antigen as well as the
precise nature of the IgA in patients with mesangial IgA
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deposition may vary from individual to individual. For this
reason, all-inclusive conclusions regarding the pathogenesis of
IgA nephropathy must be viewed cautiously. Certain features
of this entity do suggest, however, that common pathways
might lead to glomerulonephritis.
Although no histocompatibility antigens are universally pre-
sent in individuals with IgA nephropathy, the observation that
certain HLA types are more frequent in patients with this
disorder than in the general population suggests that some
individuals might be genetically predisposed to this disease [43,
92—96]. Whether their increased susceptibility is related to an
underlying disorder of immune responsiveness, to an impaired
capacity for clearing pathogenic immune reactants from the
circulation (such as a defective macrophage-phagocyte system),
to local factors intrinsic to the mucosal barrier, or to the kidney
itself has yet to be determined. There is some support for the
hypothesis that patients with IgA nephropathy have abnormal
immune responsiveness. As Dr. Egido pointed out, he and his
coworkers observed that following polyclonal stimulation, pe-
ripheral lymphocytes obtained from patients with IgA nephrop-
athy produced larger amounts of polymeric IgA than did those
obtained from normal individuals [91, 97]. On further examina-
tion these investigators observed a defect in the generation of
IgA-specific suppressor cells in the patients studied [98], an
observation also found by others [99]. They also observed that
T cells derived from patients with IgA nephropathy were more
efficient in providing helper function for IgA production in
response to mitogen stimulation than were T cells obtained
from normal controls [98]. Furthermore, an increase in circulat-
ing helper/suppressor T-cell ratios has been detected in patients
with IgA nephropathy [97, 98], and an absolute increase in
circulating IgA-specific helper T cells also has been observed
[100]. These findings suggest an underlying disorder of immune
regulation in patients with IgA nephropathy. However, the
results also could be explained by ongoing antigenic stimulation
of cells involved in the IgA immune response.
The occurrence of mesangial IgA deposits in disorders other
than idiopathic IgA nephropathy also may provide insights into
the underlying pathophysiologic disorder. For example, the
observation that IgA deposits in the mesangium are found
frequently in patients with liver disease is consistent with the
hypothesis that a primary abnormality in the macrophage-
phagocyte system of the liver results in accumulation of im-
mune reactants in the circulation and yields immune deposit
formation within the kidney. The impaired phagocytic activity
found both in vitro and in vivo in some of these patients with the
idiopathic disorder adds further support to this hypothesis [10 1—
104]. Alternatively, these findings could result from overload of
a normal phagocytic system by circulating immune reactants.
Indeed, following bile duct ligation, plasma IgA levels, circulat-
ing IgA-containing immune complexes, and mesangial IgA
deposits increase in rats [105]. Similarly, rats with carbon
tetrachloride-induced cirrhosis also develop elevated plasma
IgA levels and mesangial deposits of IgA [1061. Finally, patients
with alcoholic liver disease and primary biliary cirrhosis have
elevated plasma polymeric IgA levels [107—109]. These clinical
and experimental findings are consistent with the theory that
glomerular IgA deposition results from impaired clearance of
IgA or IgA-containing immune complexes from the circulation.
The recurrence of IgA nephropathy in patients who have
received transplanted kidneys from related or unrelated donors
suggests that the abnormality in this disorder does not lie
exclusively within the kidney [53, 110]. Furthermore, the
resolution of mesangial IgA deposits in patients who inadver-
tently received kidneys from donors with unsuspected IgA
nephropathy further supports this contention [110—112].
No direct evidence has implicated or excluded a defect in the
mucosal barrier in IgA nephropathy. As discussed by Dr.
Rodicio, however, the close temporal relationship between
respiratory and gastrointestinal infections on the one hand and
episodes of nephritis on the other is striking and suggests that
the mucosa is the site of immunologic stimulation. Patients with
IgA nephropathy have increased IgA-bearing plasma cells in
their tonsils [113]. Although the number of these cells in the
small intestine in such patients is normal [114], the pathogenic
IgA might have a mucosal or secretory origin. Because differ-
ences exist in human IgA found in serum and secretions, the
finding of secretory IgA in the kidney would support this
hypothesis. Most of the IgA in serum is monomeric (40%) and
consists predominantly (80%) of the subclass IgAl [115, 116].
Secretory IgA consists in large part of the subclass IgA2 (40%—
60%) and is predominantly polymeric; the monomeric subunits
are joined by the polypeptide J chain [115, 116]. At mucosal
sites, polymeric IgA attaches to secretory component, a small-
molecular-weight protein elaborated by epithelial cells [115,
116]. The subclass of IgA most often found in the glomerular
deposits of patients with IgA nephropathy is exclusively IgAl
[65, 110, 117—121]. But several investigators have found J chain
within the mesangial deposits in some patients [122—125].
Furthermore, the mesangial IgA binds to free secretory compo-
nent, suggesting that polymeric IgA is deposited within glomer-
uli [65, 119, 1251.
Studies of experimentally induced IgA nephropathy provide
further evidence that the IgA deposited in the kidney is poly-
meric and of mucosal origin. Rifai et a! have developed a mouse
model of IgA nephropathy induced by IgA anti-dinitrophenol
(DNP) derived from the MOPC-315 plasmacytoma and dinitro-
phenolated bovine serum albumin (DNP-BSA) [126]. They
observed that glomerular immune deposit formation depended
on the presence of both DNP-BSA and IgA anti-DNP-BSA.
However, they found that only polymeric IgA antibody pro-
duced glomerular deposits; monomeric IgA failed to do so.
Polymeric IgA is also found in the mesangium of rats with
ligated bilej ducts or carbon tetrachloride-induced cirrhosis (105,
106]. Emancipator and coworkers have developed another
mouse model of IgA nephropathy [127]. Following oral adminis-
tration of protein antigen in adjuvant, they showed that mice
develop an increase in IgA-bearing plasma cells at mucosal
sites, an increase in antigen-specific IgA antibodies in serum,
and glomerular immune deposit formation consisting of protein
antigen and mucosally derived polymeric IgA (J chain). These
studies provide strong supportive evidence that orally adminis-
tered antigens can participate in glomerular immune deposit
formation, and that glomerular IgA can be derived from a
mucosal source.
The precise mechanism of glomerular immune deposit forma-
tion in this disorder is unknown; whether the deposits result
from the deposition of circulating immune complexes or from
IgA binding to exogenous antigens located within the mesangi-
um (or vice versa) has not been determined. Circumstantial
evidence for the circulating immune complex mechanism in-
cludes the detection of complexes containing polymeric IgA in
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the circulation of some of these individuals [64, 110, 121, 128].
But the lack of functional or histologic evidence of glomerulone-
phritis following passive administration of preformed immune
complexes to normal animals makes this association question-
able [129, 130]. Whatever the mechanism of immune deposit
formation, these studies imply that polymeric IgA is pathogen-
ic, whereas monomeric IgA is not. This difference could be due
either to the influence of polymeric IgA on circulating immune
complexes, the ability of polymeric IgA to localize within the
mesangium, or the properties of deposited polymeric IgA within
the mesangium. Lowance, Mullins, and McPhaul suggested that
the pathogenic IgA might be an anti-mesangial antibody, based
on the finding that IgA eluted from the kidney of a patient with
IgA nephropathy had apparent reactivity with normal mesangi-
urn [1311. This result has not been confirmed, however [132],
Recently it was discovered that the IgA eluted from the kidneys
of patients with IgA nephropathy binds to the mesangial area of
autologous tissue, but not to normal glomeruli or glomeruli from
patients with other glomerular disorders. Moreover, approxi-
mately one-third of the IgA antibodies eluted also cross-reacted
with the mesangium of other patients with IgA nephropathy.
This finding suggests that a common antigen might exist in some
of these individuals [132]. To date, no specific antigens have
been identified.
The factors leading to glomerulonephritis following IgA depo-
sition are also unknown. The deposition of C3 and properdin,
and the paucity of the initial components of the classical
pathway suggest that activation of the alternative complement
pathway is involved [22]. This hypothesis is consistent with the
observation that IgA immunoglobulins are effective activators
of the alternate pathway, but they cannot fix complement by the
classical pathway [116]. The recent demonstration of C4 bind-
ing protein in the mesangium of some of these patients suggests
that when IgG or 1gM is present in glomeruli, activation of the
complement system via the classical pathway also might be
involved [133, 134]. Whether glomerular injury depends on
complement, or whether other mediators are involved in the
pathogenesis of glomerulonephritis has not yet been
determined.
In summary, the available clinical and experimental evidence
suggests that IgA nephropathy can occur through mucosal
immunization with polymeric IgA (subclass IgAl) deposition in
the kidney. This sequence of events probably is more likely to
occur in individuals who have either altered helper/suppressor
immune cell function or who have impaired macrophage-phago-
cytic activity. Many aspects of the pathogenesis await further
definition, including the nature of the antigens, further identifi-
cation of the pathogenic IgA, the mechanisms of immune
deposit formation, and the final mediators of glomerular injury.
Reprint requests to Dr. J. Rodicio, Servicio de Nefrologia, Ciudad
Sanitaria J0 de Ociubre, Ctra. Andalucia Km 5.400, Madrid 26, Spain
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